...
首页> 外文期刊>Human Reproduction >Improving the reporting of clinical trials of infertility treatments (IMPRINT): modifying the CONSORT statement??.
【24h】

Improving the reporting of clinical trials of infertility treatments (IMPRINT): modifying the CONSORT statement??.

机译:改善不育症治疗的临床试验报告(IMPRINT):修改CONSORT声明??。

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical trials testing infertility treatments often do not report on the major outcomes of interest to patients and clinicians and the public (such as live birth) nor on the harms, including maternal risks during pregnancy and fetal anomalies. This is complicated by the multiple participants in infertility trials which may include a woman (mother), a man (father), and result in a third individual if successful, their offspring (child), who is also the desired outcome of treatment. The primary outcome of interest and many adverse events occur after cessation of infertility treatment and during pregnancy and the puerperium, which create a unique burden of follow-up for clinical trial investigators and participants. In 2013, because of the inconsistencies in trial reporting and the unique aspects of infertility trials not adequately addressed by existing Consolidated Standards of Reporting Trials (CONSORT) statements, we convened a consensus conference in Harbin, China, with the aim of planning modifications to the CONSORT checklist to improve the quality of reporting of clinical trials testing infertility treatment. The consensus group recommended that the preferred primary outcome of all infertility trials is live birth (defined as any delivery of a live infant ≥20 weeks gestations) or cumulative live birth, defined as the live birth per women over a defined time period (or number of treatment cycles). In addition, harms to all participants should be systematically collected and reported, including during the intervention, any resulting pregnancy, and during the neonatal period. Routine information should be collected and reported on both male and female participants in the trial. We propose to track the change in quality that these guidelines may produce in published trials testing infertility treatments. Our ultimate goal is to increase the transparency of benefits and risks of infertility treatments to provide better medical care to affected individuals and couples.
机译:测试不育治疗的临床试验通常不会报告患者和临床医生以及公众感兴趣的主要结局(例如活产),也不会报告危害,包括怀孕期间的母亲风险和胎儿异常。不孕症试验的多个参与者使情况复杂化,其中可能包括女性(母亲),男性(父亲),并导致第三个人(如果成功),其后代(孩子),这也是理想的治疗结果。感兴趣的主要结果和许多不良事件发生在不育治疗停止后以及妊娠和产褥期,这给临床试验研究者和参与者带来了独特的随访负担。 2013年,由于试验报告的不一致以及现有的合并试验标准(CONSORT)声明未能充分解决不孕症试验的独特方面,我们在中国哈尔滨召开了共识会议,目的是计划对试验报告进行修改CONSORT清单可提高不育治疗的临床试验报告的质量。共识小组建议,所有不育试验的首选主要结局是活产(定义为任何≥20周的活产婴儿分娩)或累积活产,其定义为每个妇女在规定时间段内(或人数)的活产治疗周期)。此外,应系统地收集和报告对所有参与者的伤害,包括在干预过程中,任何由此而来的妊娠以及新生儿期间。应当收集常规信息,并向试验中的男性和女性参与者报告。我们建议跟踪这些指南在不育治疗测试的公开试验中可能产生的质量变化。我们的最终目标是增加不孕治疗的收益和风险的透明度,以便为受影响的个人和夫妇提供更好的医疗服务。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号